Image 1 of 1
Image 1 of 1
Image 1 of 1
Image 1 of 1
The Anti-Amyloid Treatment Journal is a guided tool designed for individuals receiving Leqembi (lecanemab) or Kisunla (donanemab) and for the caregivers who support them. Created to bring calm, clarity, and confidence throughout the treatment journey, this journal helps users track infusions, monitor side effects, document MRI and ARIA results, and record daily observations related to memory, mood, and overall well-being.
With thoughtfully organized sections for appointment notes, care team contacts, lab results, and reflection prompts, the journal encourages a holistic approach to Alzheimer’s care. It empowers caregivers to communicate more effectively with neurologists, infusion centers, and family members—while keeping essential information in one easy-to-use place.
Whether used as part of a clinical trial or during FDA-approved treatment, the Anti-Amyloid Treatment Journal offers peace of mind and practical structure for navigating the complexities of anti-amyloid therapy.
The Anti-Amyloid Treatment Journal is a guided tool designed for individuals receiving Leqembi (lecanemab) or Kisunla (donanemab) and for the caregivers who support them. Created to bring calm, clarity, and confidence throughout the treatment journey, this journal helps users track infusions, monitor side effects, document MRI and ARIA results, and record daily observations related to memory, mood, and overall well-being.
With thoughtfully organized sections for appointment notes, care team contacts, lab results, and reflection prompts, the journal encourages a holistic approach to Alzheimer’s care. It empowers caregivers to communicate more effectively with neurologists, infusion centers, and family members—while keeping essential information in one easy-to-use place.
Whether used as part of a clinical trial or during FDA-approved treatment, the Anti-Amyloid Treatment Journal offers peace of mind and practical structure for navigating the complexities of anti-amyloid therapy.